Enterprise Value

33.33M

Cash

40.39M

Avg Qtr Burn

-18.86M

Short % of Float

8.49%

Insider Ownership

0.52%

Institutional Own.

38.65%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PreHevbrio (Sci-B-Vac®) Details
Hepatitis B vaccine, Hepatitis B, Pain

Approved

Quarterly sales

VBI-2601 (HBV Immuno-Therapeutic) Details
Chronic hepatitis B, Hepatitis B, Surgical site infection

Phase 2

Data readout

VBI-1901 (eVLP) Details
Glioblastoma, Metabolic disorder, Cancer

Phase 2

Initiation

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1

Data readout